More precisely, 30% fewer patients reported one or more falls compared to placebo. Since some patients may have had several falls (or 100 falls) and others only one, there could have been more falls, the same falls or fewer falls in total on a per patient basis on drug than placebo.
In the big scheme of things, I am not too worried about A273's side effect profile. For the most part, it is worse than placebo as would be expected, but so are most CNS medications. Falls were slightly better, dizziness and confusion worse. Far more dropouts occurred on drug than placebo. Confusion and dizziness will lead to some patients discontinuing the medication. In the case of donepezil its GI upset as main issue. For those reasons, the most important way to look at tolerability related adverse events is to figure out whether they lead to discontinuations not whether a person just has a few days of symptoms. More patients on A273 dropped out due to tolerability but not so many as to disqualify the drug.
News 
Market Data 
Discover 
